Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma.
The breaking of peripheral T-cell tolerance toward self-antigens expressed by tumor cells and the subsequent establishment of an effective tumor protective immune response remains a major challenge for cancer immunotherapy. We report that both protective and therapeutic anti-tumor immune responses can be achieved in a mouse leukemia/lymphoma tumor model through the strong adjuvant effects provided by allogeneic CD3/CD28 cross-linked Th1 memory cells. The adjuvant effect of these cells is mediated by their ability to produce a variety of 'danger signals' which serve to deviate native non-protective Th2 anti-leukemia immune responses to effective Th1 immune responses.
Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah-Hebrew University Medical Center, Jerusalem, 91120, Israel. harnoy@immunovative.co.il
M
M
Har-Noy
M
M
Zeira
L
L
Weiss
E
E
Fingerut
R
R
Or
S
S
Slavin
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D018106:CD28 Antigens / Q000276:immunology; D017252:CD3 Complex / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology; D002454:Cell Differentiation / Q000276:immunology; D019938:Cyclin D1 / Q000276:immunology; D005260:Female; D007156:Immunologic Memory; D016233:Immunotherapy, Active / Q000379:methods*; D007938:Leukemia / Q000276:immunology / Q000628:therapy*; D008223:Lymphoma / Q000276:immunology / Q000628:therapy*; D008297:Male; D051379:Mice; D018417:Th1 Cells / Q000166:cytology / Q000276:immunology / Q000637:transplantation*; D014184:Transplantation, Homologous / Q000276:immunology*
D000951:Antigens, Neoplasm; D018106:CD28 Antigens; D017252:CD3 Complex; D019496:Cancer Vaccines; D019938:Cyclin D1